Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 10th January 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

PetMedix and Zoetis to collaborate on antibody therapies
"Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets" - Robert J. Polzer, Zoetis.

Firms will use transgenic platforms for antibody discovery.

PetMedix has joined forces with Zoetis to develop new species-specific
animal monoclonal antibody therapies (mAbs) using its proprietary transgenic platforms.

Through the partnership, PetMedix will carry out discovery activities against a number of key targets, while Zoetis will have exclusive rights to develop and bring these therapies to market.

Having already brought three novel mAbs to market, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies.

PetMedix chief executive Dr Tom Weaver commented: "We are excited to be partnering with Zoetis. Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination."

While many technologies have been used to develop human therapeutic antibodies, 40 years of research highlights the benefits of antibodies which are 100 per cent species-matched to the patient.

PetMedix is looking to build on this success for companion animals. Its Ky9™ and Felyne™ platforms were developed in the same way as the leading human transgenic platforms. The collaboration also marks the third publicly-announced deal Zoetis has made with companies using transgenic platforms for antibody discovery.

Zoetis executive vice president and president Robert J. Polzer, said: "At Zoetis, we are committed to continuing our leadership to develop and discover new therapeutic antibodies that can help pets live longer, healthier lives. Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets."

Image (C) PetMedix.

Become a member or log in to add this story to your CPD history

Birmingham Dogs Home makes urgent appeal

News Story 1
 Birmingham Dogs Home has issued an urgent winter appeal as it faces more challenges over the Christmas period.

The rescue centre has seen a dramatic increase in dogs coming into its care, and is currently caring for over 200 dogs. With rising costs and dropping temperatures, the charity is calling for urgent support.

It costs the charity £6,000 per day to continue its work.

Fi Harrison, head of fundraising and communications, said: "It's heart-breaking for our team to see the conditions some dogs arrive in. We really are their last chance and hope of survival."

More information about the appeal can be found here. 

Click here for more...
News Shorts
Avian flu confirmed at premises in Cornwall

A case of highly pathogenic avian influenza H5N1 has been detected in commercial poultry at a premises near Rosudgeon, Cornwall.

All poultry on the infected site will be humanely culled, and a 3km protection zone and 10km surveillance zone have been put in place. Poultry and other captive birds in the 3km protection zone must be housed.

The case is the second avian flu case confirmed in commercial poultry this month. The H5N5 strain was detected in a premises near Hornsea, East Riding of Yorkshire, in early November. Before then, the disease had not been confirmed in captive birds in England since February.

The UK chief veterinary officer has urged bird keepers to remain alert and practise robust biosecurity.

A map of the disease control zones can be found here.